Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy.
- 1UC Irvine
Abstract
Heat shock protein family B member 8 (HSPB8) is a chaperone involved in the chaperone-assisted selective autophagy (CASA) complex. HSPB8 in conjunction with cochaperone Bcl2-associated athanogene 3 (BAG3), promotes autophagy-mediated removal of misfolded proteins associated with various neurodegenerative diseases. Mutations in HSPB8, previously associated with Charcot Marie Tooth disease type 2L, have recently been linked to an autosomal dominant rimmed vacuolar myopathy (MFM13), and is considered a multisystem proteinopathy. Patients have distal and proximal limb girdle myopathy with muscle biopsy showing fatty replacement, endomysial fibrosis, and rimmed vacuoles leading to muscle atrophy and early demise. We have demonstrated reduced expression of HSPB8, altered autophagy, and TAR DNA-binding protein 43 (TDP-43) accumulation in patient fibroblasts. Overexpressed murine Hspb8 frameshift mutant (c.515dupC, fs) displays insolubility and aggregation propensity in Murine Neuroblastoma X Spinal Cord 34 (NSC-34) cells. Using clustered regularly interspaced short palindromic repeats (CRISPR) technology, we generated a knock-in Hspb8 mouse model of the c.515dupC hot spot frameshift variant to study disease pathology. Mutant Hspb8 mice developed late onset muscle weakness beginning at 15 months. Muscle biochemical analyses revealed reduced HSPB8 levels, increased TDP 43, and altered autophagy markers, partially recapitulating the human phenotype. Fiber type analysis, neuromuscular junction integrity, and motor neurons show mild myopathy without neurodegeneration. Given the lack of available treatments, we evaluated trehalose, a natural disaccharide that is known to induce HSPB8 and enhance autophagy as a potential therapy. Administration of 2% trehalose in the drinking water restored HSPB8 expression; however, it did not significantly ameliorate autophagic dysfunction or TDP-43 pathology in mutant mice. These findings support the value of our preclinical models for translational studies, and autophagy enhancement as a potential therapeutic strategy for HSPB8-related myopathy.
Related
- Screening and characterization of endophytic bacterial isolates associated with Echinops kebericho M. and Lepidium sativum L. and evaluation of their potential role
- Case Report: Pallister-Hall syndrome associated with a previously unreported de novo GLI3 frameshift variant and diagnostic insights from the Middle East
- Discovery of frameshift-associated TCRs following personalized neoantigen vaccination in a patient with osteosarcoma
- Quantitative characterization of PP2A-derived peptides modulating the LRRK2:PP2A protein-protein interaction
- Predicting and finding geroprotective compounds through modulating conserved longevity–associated aging modules
BibTeX
@misc{shmara2026characterization,
title = {{Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy.}},
author = {A. Shmara and L. Weiss and A. Gromova and B. Tedesco and P. Pal and G. Kostalnick and V. Boock and E. Bassett and S. Parera and C. Cheng and L. M. Ta and J. Lee and A. Panchagatti and E. Mohanty and J. Vu and A. R. La Spada and A. Poletti and V. Kimonis},
howpublished = {bioRxiv},
year = {2026},
month = aug,
doi = {10.64898/2026.08.04.742148},
url = {https://www.biorxiv.org/content/10.64898/2026.08.04.742148v2},
note = {CC BY},
}
RIS
TY - UNPB
TI - Characterization of the frameshift c.515dupC knock-in mouse model of HSPB8-associated myopathy (MFM13) and evaluation of Trehalose as autophagy modulating therapy.
AU - A. Shmara
AU - L. Weiss
AU - A. Gromova
AU - B. Tedesco
AU - P. Pal
AU - G. Kostalnick
AU - V. Boock
AU - E. Bassett
AU - S. Parera
AU - C. Cheng
AU - L. M. Ta
AU - J. Lee
AU - A. Panchagatti
AU - E. Mohanty
AU - J. Vu
AU - A. R. La Spada
AU - A. Poletti
AU - V. Kimonis
PY - 2026
DA - 2026/08/04
PB - bioRxiv
DO - 10.64898/2026.08.04.742148
UR - https://www.biorxiv.org/content/10.64898/2026.08.04.742148v2
AB - Heat shock protein family B member 8 (HSPB8) is a chaperone involved in the chaperone-assisted selective autophagy (CASA) complex. HSPB8 in conjunction with cochaperone Bcl2-associated athanogene 3 (BAG3), promotes autophagy-mediated removal of misfolded proteins associated with various neurodegenerative diseases. Mutations in HSPB8, previously associated with Charcot Marie Tooth disease type 2L, have recently been linked to an autosomal dominant rimmed vacuolar myopathy (MFM13), and is considered a multisystem proteinopathy. Patients have distal and proximal limb girdle myopathy with muscle biopsy showing fatty replacement, endomysial fibrosis, and rimmed vacuoles leading to muscle atrophy and early demise. We have demonstrated reduced expression of HSPB8, altered autophagy, and TAR DNA-binding protein 43 (TDP-43) accumulation in patient fibroblasts. Overexpressed murine Hspb8 frameshift mutant (c.515dupC, fs) displays insolubility and aggregation propensity in Murine Neuroblastoma X Spinal Cord 34 (NSC-34) cells. Using clustered regularly interspaced short palindromic repeats (CRISPR) technology, we generated a knock-in Hspb8 mouse model of the c.515dupC hot spot frameshift variant to study disease pathology. Mutant Hspb8 mice developed late onset muscle weakness beginning at 15 months. Muscle biochemical analyses revealed reduced HSPB8 levels, increased TDP 43, and altered autophagy markers, partially recapitulating the human phenotype. Fiber type analysis, neuromuscular junction integrity, and motor neurons show mild myopathy without neurodegeneration. Given the lack of available treatments, we evaluated trehalose, a natural disaccharide that is known to induce HSPB8 and enhance autophagy as a potential therapy. Administration of 2% trehalose in the drinking water restored HSPB8 expression; however, it did not significantly ameliorate autophagic dysfunction or TDP-43 pathology in mutant mice. These findings support the value of our preclinical models for translational studies, and autophagy enhancement as a potential therapeutic strategy for HSPB8-related myopathy.
ER -